Discrimination of single nucleotide mismatches using a scalable, flexible, and transparent three-dimensional nanostructure-based plasmonic miRNA sensor with high sensitivity by �넀�삙�쁺 & �뿀�슜誘�
Contents lists available at ScienceDirect
Biosensors and Bioelectronics
journal homepage: www.elsevier.com/locate/bios
Discrimination of single nucleotide mismatches using a scalable, ﬂexible,
and transparent three-dimensional nanostructure-based plasmonic miRNA
sensor with high sensitivity
Hee-Kyung Naa, Jung-Sub Wia, Hye Young Sonb, Jong G. Okc, Yong-Min Huhb, Tae Geol Leea,⁎
a Center for Nano-Bio Measurement, Korea Research Institute of Standards and Science (KRISS), Daejeon 34113, Republic of Korea
bDepartment of Radiology, College of Medicine, Yonsei University, Seoul 03722, Republic of Korea
c Department of Mechanical and Automotive Engineering, Seoul National University of Science and Technology, Seoul 01811, Republic of Korea
A R T I C L E I N F O
Keywords:
LSPR biosensor
miRNA sensing
Scalable plasmonic nanostructure
Single base mismatch discrimination
A B S T R A C T
Localized surface plasmon resonance (LSPR) biosensors have attracted much interest due to their capacity for
multiplexing, miniaturization, and high performance, which oﬀers the potential for their integration into lab-on-
a-chip platforms for point-of-care (POC) diagnostics. The need for microRNA (miRNA)-sensing platforms is
particularly urgent because miRNAs are key regulators and biomarkers in numerous pathological processes and
diseases. Unfortunately, however, development of such miRNA-sensing platforms has not yet been achieved. In
order to realize the detection of these important biomarkers, there has been an increasing demand for POC-
sensing platforms that enable label-free quantiﬁcation with low sample consumption, good sensitivity, real-time
responsiveness, and high throughput. Here, we developed a highly speciﬁc, sensitive LSPR miRNA-sensing
platform on a ﬂexible, scalable plasmonic nanostructure to enable single-base mismatch discrimination and
attomole detection of miRNAs in clinically relevant samples. The hairpin probe contained a locked nucleic acid
(LNA) that enabled the discrimination of single base mismatches based on diﬀerences in melting temperatures of
perfectly matched or single base mismatched miRNAs when they formed base pairs with probes. In addition,
through hybridization induced signal ampliﬁcation based on precipitate formation on the gold surface through
the enzyme reaction, we observed a dramatic LSPR peak shift, which enabled attomole detection. Additionally,
our LSPR miRNA sensor enabled the detection of miR-200a-3p in total RNA extracts from primary cancer cell
lines without puriﬁcation or labeling of the miRNA. This label-free and highly speciﬁc miRNA sensing platform
may have applications in POC cancer diagnostics without the need for gene ampliﬁcation.
1. Introduction
MicroRNAs (miRNAs) are endogenous, noncoding RNAs that are
short in length (19–22 nt) and involved in numerous biological pro-
cesses (Bartel, 2004; Zhang et al., 2007; Ambros, 2004). The expression
of various miRNAs is associated with a wide range of diseases, including
cancer, neurodegenerative disorders, and diabetes (Lu et al., 2005;
Calin and Croce, 2006; Esquela-Kerscher and Slack, 2006; Liu et al.,
2012; Brennan et al., 2017). Hence, the accurate detection of the ex-
pression levels of one or more miRNAs could facilitate their wide-ran-
ging applications as diagnostic and prognostic biomarkers (Kanwal
et al., 2017; Jang et al., 2017; Dou et al., 2017; Jones et al., 2012).
However, their low abundance in bioﬂuids, fragile structure, small size,
and sequence similarity among family members have been vexing im-
pediments to the development of ultrasensitive and highly speciﬁc
sensing platforms (Hunt et al., 2015; Catuogno et al., 2011).
Various miRNA detection methods, including real-time quantitative
polymerase chain reaction (PCR), ﬂuorescence, and electrochemical
sensing platforms, have been developed; however, these methods re-
quire ampliﬁcation and labeling, and are hindered by diﬃculties in
quantitative detection when using clinically relevant samples (Lee
et al., 2015; Ryoo et al., 2013; Su et al., 2016; Tian et al., 2013). As
such, there has been an increased demand for platforms that enable
quantitative miRNA sensing without labeling and ampliﬁcation and
that can be easily implemented and developed into point-of-care (POC)
diagnostic systems (Cardoso et al., 2016; Dorvel et al., 2012; Pang et al.,
2016). In addition, for practical bioanalytical and clinical applications
using cell extracts, the miRNA biosensors must exhibit reproducible
signal generation, high speciﬁcity capable of single-base mismatch
discrimination, high-throughput capability for simultaneous detection
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of various targets and samples, and high sensitivity (Xiao et al., 2009a;
Xiao et al., 2009b; Wei et al., 2016; Huang et al., 2015).
Localized surface plasmon resonance (LSPR) biosensors exploit a
phenomenon in which the binding of an analyte to the surface of a
nanostructure induces a change in the local refractive index, resulting
in a wavelength shift (Lee et al., 2011; Sepúlveda et al., 2009). As a
result, LSPR biosensors are able to facilitate sensitive and label-free
quantiﬁcation of biomolecules using simple instrumentation (Mayer
et al., 2008; Yang et al., 2016). Moreover, they oﬀer the potential for
multiplexed, miniaturized assays with straightforward implementation
and high performance that can be applied to lab-on-a-chip or POC de-
vices (Song et al., 2017); Park et al., 2017). Chip-based LSPR biosensors
have advantages over platforms that consist of colloidal nanoparticles
because their use allows the user to avoid the tedious washing/cen-
trifugation process without being concerned about stability in the
buﬀers and biological samples (Guo et al., 2017). The fabrication
strategy utilized to obtain three-dimensional (3D) plasmonic nanos-
tructures on large-scale substrates for integration into various types of
lab-on-a-chip and high-throughput sensing platforms must be cost-ef-
fective, reproducible, ﬂexible, and scalable (Thilsted et al., 2016;
Stewart et al., 2008). Thus, much eﬀort has been made to fabricate 3D
plasmonic nanostructures that satisfy these requirements (Verellen
et al., 2011; Cetin and Altug, 2012; Wi et al., 2013). For practical ap-
plications, the fabrication strategy should also be straightforward. Be-
cause accurate disease diagnosis and prognosis depend on determining
the type and stage of the speciﬁc disease, it is important that the
miRNAs be detected and quantiﬁed with high accuracy, sensitivity, and
throughput (Tian et al., 2012; Wong et al., 2015; Li et al., 2014; Labib
et al., 2013). In this study, we oﬀer a new strategy to produce a highly
sensitive LSPR miRNA sensing platform that is capable of single-base
mismatch discrimination on a ﬂexible, scalable 3D plasmonic nanos-
tructure. For the 3D plasmonic nanostructure, we fabricated uniform
gold strips on a 4-in.-scale substrate through a simple, cost-eﬀective
procedure. To generate a distinguishable, reproducible, large LSPR
peak shift in the presence of the target miRNA, a signal ampliﬁcation
strategy using a well-designed probe structure was utilized, resulting in
a device with high performance and sequence speciﬁcity.
2. Materials and methods
2.1. Electromagnetic simulation
Electromagnetic simulations were performed using two-dimensional
(2D) ﬁnite-diﬀerence time-domain software (Lumerical FDTD solution
8.9). To calculate the absorbance curves, a simulation mesh was set to a
0.1-nm square grid. The refractive indices of the substrate and organic
layer were assumed to be constants of 1.5 and 1.6, respectively. To
simulate the arrayed nanostructures, a perfectly matched layer was
used as the boundary condition for the z-axis, and periodic boundary
conditions with 200 nm periodicity were used for the x- and y-axes. The
modeled structure in a uniform dielectric medium (n= 1.33) was il-
luminated from the top with a linearly polarized plane wave.
2.2. SAM formation
The sequences for the miRNAs, hairpin probes, and signaling probes
are available in the supplementary information section. Wafer-sized
plasmonic nanopatterns were cut into small pieces, ﬁtted in a cuvette or
16-well chamber and the small pieces of patterns were washed with
ethanol and water. Synthesized LNA probes were diluted to 10 µM
concentration in phosphate-buﬀered saline (PBS) and annealed at 95 °C
for 5min with a gradual temperature decrease down to 4 °C. A solution
of the thiol-modiﬁed and annealed probe in PBS was introduced to the
gold nanopattern with the same concentration of 3-mercapto-1-pro-
panol and incubated overnight. The sensor modiﬁed with the probe was
washed with PBS ﬁve times.
2.3. Detection of miRNA
The sensor modiﬁed with a probe was treated with a predetermined
concentration of miRNA in buﬀer (or in total RNA dissolved in PBS)
overnight at room temperature. For miRNA detection in total RNA,
extracted total RNA was quantiﬁed using Take3 plates in SynergyH1
(Biotek, UK) and dissolved in PBS. Then, the mixture was incubated in
70 °C for 1 h and followed by washing with PBS three times at 70 °C for
10min. After washing, the sensor in PBS was cooled down to 4 °C. The
signal sequence shown above was dissolved in PBS at a concentration of
500 nM and was applied to the sensor. After incubation for 3 h, the
sensor was washed with PBS three times, and incubated with 1% bovine
serum albumin (BSA) in the PBS for 1 h. Streptavidin-horseradish per-
oxidase (HRP) conjugate solution in 1% BSA in PBS was added to the
sensor at a concentration of 25 µg/mL for 1 h. After repeated washing
with PBS, the sensor was incubated with a mixture of 980 µL of 4-
chloronaphthol solution and 20 µL of 100mM H2O2 for 10min.
Absorbance spectra of plasmonic sensors were obtained using a UV–vis
spectrophotometer (UV-2600; Shimadzu, Japan) or microplate reader
(SynergyH1; Biotek, Winooski, VT, USA).
3. Results and discussion
3.1. Fabrication of 3D plasmonic nanostructure
Fig. 1 depicts the signal ampliﬁcation strategy used to accurately
detect miRNAs on 3D nanostructures on gold strips. Brieﬂy, the 3D
plasmonic gold nanostructure was fabricated via roll-to-roll nanoim-
print lithography (R2R NIL) followed by Au deposition (Wi et al., 2017;
Ahn and Guo, 2009). The Au strips were then formed by thermal eva-
poration of gold with a deposition angle of 35° on polyurethane acrylate
(PUA) nanogratings obtained by R2R NIL using a polydimethylsiloxane
mold to generate the 200-nm period and 100-nm nanograting pattern.
In our tests, the Au strips provided the potential for high-throughput
analysis (Fig. S1a), and the ﬂexible, transparent 3D nanostructure
conferred beneﬁts related to easy integration in various types of lab-on-
a-chip and POC diagnostic devices. In addition, the inverted “L” shape
of the gold nanostructures obtained by Au deposition on the top and
sidewall surfaces of the PUA nanogratings (using a controlled oblique
deposition angle) enabled the formation of a surface plasmon with a
long oscillation length, which is known to have enhanced refractive
index sensitivity compared to the rod-shaped Au deposited structure at
the top (Miller and Lazarides, 2005; Larsson et al., 2007; Kazuma and
Tatsuma, 2014). The 3D gold nanostructures were characterized by
scanning electron microscopy (SEM) and ultraviolet-visible spectro-
scopy. SEM images indicate that our nanofabrication facilitated the
formation of uniform patterns and a unique gold deposited structure, as
shown in Fig. 2a. The absorbance curve showed characteristics of
plasmonic nanostructures in phosphate-buﬀered saline (PBS), as shown
in Fig. 2b. Two characteristic peaks were observed at the wavelengths
of 760 nm and 605 nm, which originate from the oscillation of the
surface plasmon of the entire Au strip and the oscillation of the surface
plasmon in the internal segments of the line array such as the Au ﬁlm on
the top, respectively.
3.2. Signal ampliﬁcation for miRNA detection
To obtain an easily distinguishable and reproducible LSPR peak
shifts in buﬀer, the signal ampliﬁcation strategy used was based on
precipitate formation of the substrate via an enzymatic reaction. To
induce target-speciﬁc precipitate formation, our probe was designed to
have a hairpin structure that consisted of a fully complementary se-
quence against the target, causing a conformational change to the
double-stranded form in the presence of a fully matched target mole-
cule, accompanied by thermal destabilization of a partially hybridized
sequence with mismatched miRNA. The probe was further designed to
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allow the binding of a horseradish peroxidase (HRP)-streptavidin con-
jugate to a biotin-labeled signal sequence to trigger the conversion of
the soluble substrate into an insoluble precipitate in the presence of the
target miRNA. In addition, locked nucleic acid (LNA), which forms a
covalent bond between the 2′ oxygen and 4′ carbon of the ribose ring,
was chosen as a probe due to its enhanced aﬃnity to complementary
RNA, enabling the discrimination of single-base mismatches (You et al.,
2004; Owczarzy et al., 2011; Braasch and Corey, 2001). To demonstrate
the usefulness of our strategy in detecting clinically relevant miRNAs,
we chose the let-7 miRNA family as a target miRNA because they
contain a perfectly matched target (let-7a) and single nucleotide-sub-
stituted targets (let-7c and let-7f) to observe the ability of our sensor to
detect single base mismatches, as well as miR-200a, which is a known
prognostic and diagnostic cancer biomarker (Li et al., 2015; Matsuura
et al., 2016; Meng et al., 2016; Masood and Yasmin, 2017).
To predict the feasibility of our strategy, the LSPR peak shift was
estimated by a calculation that used a two-dimensional ﬁnite diﬀerence
time domain (FDTD) simulation according to changes in the sur-
rounding organic layer. In the FDTD simulation, 30-nm-thick gold strips
(100 nm wide at the top and 120 nm in height) were modeled as a
function of thickness of the organic layer. The calculated spectra ex-
hibited noticeable peak shifts that depended on the thickness of the
organic layer on the Au strips, suggesting that the LSPR biosensor could
be designed to generate a large absorbance peak shift by controlling
target-speciﬁc insoluble precipitate formation (Fig. 2c–e).
To assess the performance of our LSPR miRNA sensor, the annealed
thiol-terminated hairpin LNA probe and mercapto-propanol were in-
troduced onto the Au strips, followed by conformational changes upon
hybridization in the presence of the target miRNA. The hybridization-
induced binding of the biotin-containing signal sequence further trig-
gered the enzyme-based precipitation of 4-chloronaphthol by the HRP-
streptavidin conjugate, which is commonly used in enzyme-linked im-
munosorbent assays (ELISAs) and other biological assays. Since
hybridization alone barely induces a distinguishable LSPR peak shift
due to small changes in the refractive index (particularly in buﬀer),
signal ampliﬁcation was required for reproducible and sensitive analyte
sensing (Fig. S2) (Elhadj et al., 2004). In addition, LPSR changes of even
several nanometers often cause poor reproducibility and accuracy in
measurements and data interpretation, particularly with instrumenta-
tion used for high-throughput analysis (Wang and Tang, 2015; Xu et al.,
2016). However, because enzymatic precipitation of the substrate was
controlled in a target-speciﬁc manner, our LSPR sensor showed a large
peak shift (up to 37 nm) in the presence of 100 nM let-7a in PBS in
Fig. 3a. SEM images shown in Fig. 3c and d provide decisive evidence of
precipitate formation in the presence of miRNA compared with the
observed line pattern in the absence of miRNA (Fig. S3). Furthermore,
precipitate formation occurred uniformly over a large area, indicating
successful formation of a self-assembled monolayer and hybridization
with target miRNA over the entire area of the gold pattern (Fig. S4). In
addition, the sensing platform produced a concentration-dependent
LSPR peak shift, as shown in Fig. 3b. Using various concentrations of
miRNA samples in buﬀer, the limit of detection (LOD) was calculated as
13 fM (2.6 attomole in 200 µL) according to the following equation:
LOD=3.3 (SD / S), where SD is the standard deviation, and S is the
slope of the calibration curve (Fig. S5). Thus, our signal ampliﬁcation
strategy on the gold nanostructure enabled sensitive target detection in
a buﬀer solution based on reproducible signal generation with a dis-
tinguishable LSPR shift. Since our signal ampliﬁcation strategy resulted
in a large LSPR shift in buﬀer with high sensitivity comparable to
previous reports (Johnson and Mutharasan, 2014), our miRNA sensing
platform has a large potential in overcoming the issue of reproduci-
bility.
3.3. Discrimination of single base mismatches
Next, we investigated the single-base mismatch discrimination
Fig. 1. Schematic of the signal-ampliﬁed LSPR miRNA sensing platform on a scalable, ﬂexible, transparent three-dimensional (3D) plasmonic nanostructure. a) Self-
assembled monolayer (SAM) formation with a hairpin LNA probe, b) hybridization with miRNAs at elevated temperature followed by treatment with a biotinylated
signaling probe, and c) binding with HRP-streptavidin followed by enzymatic reaction converting soluble substrate to insoluble precipitate.
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capability of our sensor to assess the sequence speciﬁcity for target
miRNA. The ability to discriminate single base mismatches is im-
portant, as many miRNAs have sequence similarities among diﬀerent
short miRNA (Roush and Slack, 2008; Qiu et al., 2014). The miR-let-7
family of miRNAs was chosen to investigate the potential of our sensor
to discriminate between mismatched sequences. We checked the sensor
performance with respect to the LSPR shift in the presence of miR-let-7a
as a perfectly matched target as well as miR-let-7c and let-7f, which
contain single nucleotide diﬀerences in their sequences (Fig. 4a and b).
Single-base mismatch discrimination was achieved through incubation
and washing at 70 °C, resulting in denaturation of the thermally un-
stable base pairing between the LNA probe and mismatched miRNA.
Interestingly, no signiﬁcant changes were observed in the presence of
miR-let-7c and miR-let-7f compared with the large LSPR peak shift that
was observed with miR-let-7a, revealing that our LSPR sensor was
capable of sequence-speciﬁc recognition of a perfectly matched target
(Fig. 4a). Because of the observed discrimination between miR-let-7
family members, our LNA-modiﬁed LSPR sensor has the potential to be
a platform for highly speciﬁc miRNA sensing to distinguish nonspeciﬁc
sequences containing only a single nucleotide substitution.
3.4. miRNA detection in a 16-well chamber
We then examined the applicability of our sensor for high-
throughput analysis. Our 3D gold nanostructure was processed into a 4-
in. wafer-scale substrate, and a multi-well format was easily produced.
In a 16-well chamber format, we were able to perform the same pro-
cedure described above and measure the LSPR peak changes using a
microplate reader (Fig. S1b). The data showed a remarkable LSPR peak
shift in a miRNA concentration-dependent manner. Thus, we found that
our system worked in a multi-well format for use with a microplate
reader, indicating its potential use for high-throughput analyses with
various POC diagnostic devices based on their scalable and ﬂexible
nanofabrication strategies. Because of well-established microﬂuidic
systems, our ﬂexible and scalable plasmonic nanostructure possesses
great potential to be integrated into lab-on-a-chip-based diagnostic
devices for further improved performance.
3.5. miRNA detection in total RNA extracts from primary cancer cell lines
For diagnostic and prognostic applications, the sensitive detection
of miRNAs from biologically relevant samples is essential, and while
total RNA can be easily extracted from cells, tissues, or other biological
samples, direct detection of a target miRNA from total RNA without
ampliﬁcation is diﬃcult due to its low abundance and sequence simi-
larity in a complex system. With this background, we tested miRNA
detection from cell extracts using our sensor. To investigate the sensor
performance in biological samples, two diﬀerent human primary gastric
cancer cell lines (MKN45 and SNU1) were chosen based on their miR-
200a-3p expression levels, as determined by qRT-PCR. Prior to the de-
tection of miRNA from cell extracts, we compared the sensor perfor-
mance in the presence of spiked-in 10 nM miRNAs in buﬀer or a total
RNA mixture. The treatment containing miR-200a-3p in buﬀer or a total
RNA sample isolated from SNU1 cells induced a similar LSPR peak shift,
indicating that the hairpin probe could be hybridized with target
miRNA without interference in the presence of large amounts of non-
speciﬁc RNAs (0.04% of spiked-in miRNA in total RNA in the sample,
Fig. S6).
Finally, we examined whether the sensor could be utilized to detect
a target in a biological sample. We observed a speciﬁc and distin-
guishable LSPR peak shift on modiﬁed Au strips that were com-
plementary to miR-200a-3p in total RNA extracts from miR-200a-3p-
Fig. 2. Characterization of the 3D gold nanostructure obtained by angled Au deposition on transparent polymer nanograting (a, b) and FDTD simulation for
formation of an organic layer on the 3D gold nanostructure for modeling the enzyme substrate precipitation in the presence of target miRNA (c–e). (a) SEM images of
gold patterns. Scale bar: 4 µm (inset: 400 nm). (b) Measured absorbance spectrum of the 3D gold nanostructure in PBS. Blue line: absorbance spectrum of line array
before Au deposition, and red line: absorbance spectrum after Au deposition. (c) Schematic illustration of the cross-sectional view for the FDTD simulation. (d, e)
FDTD simulation results. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.).
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Fig. 3. Sensitivity of the LSPR miRNA-sensing platform on the gold line pattern in buﬀer. (a) LSPR spectra of patterns after incubation in the absence (gray) or
presence of target miRNA (black). (b) Concentration-dependent LSPR shifts in the presence of miR-let-7a. (c, d) SEM images of Au strips after enzyme substrate
precipitation in the absence (c) and presence (d) of target miRNA. Scale bar: 2 µm (inset: 500 nm).
Fig. 4. Sequence speciﬁcity of the LSPR sensor for miRNA. (a) LSPR spectra of the pattern after incubation in the absence (green) or presence of miR-let-7c (blue),
miR-let-7f (gray), or miR-let-7a (red, 25 nM each). (b) Probe sequence for miR-let-7a detection and sequences of miR-let-7a, miR-let-7c, and miR-let-7f. Mismatch
positions in miRNA sequences are in red. LNA positions are underlined and in bold. (c) miR-200a-3p detection in total RNA extracts from human stomach adeno-
carcinoma cells. (d) LSPR peak shift in total RNA from human primary gastric cancer cells expressing (MKN45) and not expressing (SNU1) miR-200a-3p and
quantiﬁcation of miR-200a-3p in each cell line by qRT-PCR. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version
of this article.).
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expressing MKN45 cells, but not SNU1 cells that did not express miR-
200a-3p, consistent with the qRT-PCR results (Fig. 4c and d). These
results have implications for miRNA detection and quantiﬁcation, since
many RNAs in total RNA extracts can interfere with the hybridization of
a probe with its target by competitive binding of molecules having
sequence similarity, thereby reducing the sensitivity and speciﬁcity of
the sensor. However, our sensor exhibited target-speciﬁc sensing in the
presence of numerous structurally similar RNA molecules in biological
samples.
4. Conclusion
In conclusion, we have demonstrated a new strategy for ultra-
sensitive LSPR sensing of miRNA with high sequence speciﬁcity on a
straightforward, scalable, ﬂexible, and transparent 3D plasmonic na-
nostructure. Signal ampliﬁcation strategy together with the use of an
LNA-modiﬁed probe resulted in a distinguishable LSPR peak shift and
attomole detection of miRNA as well as single base mismatch dis-
crimination without labeling, reverse transcription, or gene ampliﬁca-
tion, which are required steps in qRT-PCR. To the best of our knowl-
edge, our platform showed the largest signal changes ever observed in
an LSPR miRNA sensor. In addition, our platform appeared to be well
suited for clinical applications of biomarker detection. We believe that
our LSPR miRNA sensing platform will broaden the applicability of
LSPR biosensors as simple, portable, and low-cost POC devices for
personalized prognostic and diagnostic miRNA proﬁling. However,
since the analysis time of our LSPR miRNA sensing platform is still too
long to use for direct application as a POC diagnostic tool in clinical
applications, we are currently working to shorten the analysis time to
within 1–2 h by integrating LSPR miRNA analysis platform into a mi-
croﬂuidic device and using a reaction cocktail based on nanomaterials.
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